Listing 13.11 Skeletal System Cancer in 2026

By Anthony Albert, Benefits Research Director at Disability Exchange · Published 2026-08-03 · 12-minute read

Bone cancer is rare. About 3,970 new cases of primary bone and joint cancer will hit US oncology clinics in 2026, and roughly 2,140 people will die of the disease this year, based on American Cancer Society projections. Osteosarcoma leads the pack in kids and young adults. Chondrosarcoma dominates in adults over 40. Ewing sarcoma sits in the middle age band. Chordoma is the rare skull-base and sacrum tumor with its own biology.

SSA folds all of them into Listing 13.11 under the cancer body system. If you're reading this, you've already been diagnosed and you want to know whether your case qualifies you for SSDI or SSI on medical grounds, and how quickly you can get paid. The short version: Listing 13.11 gives you three ways in. Meet any one prong and the medical piece is done. This article walks through all three, plus the treatment realities that shape whether SSA reads your case as truly disabling.

The Listing 13.11 rule in plain English

Here's the exact three-prong structure from SSA's Blue Book Listing 13.11:

• A. Sarcoma that is inoperable or unresectable.
• B. Sarcoma that is recurrent, except for local recurrence that has been controlled by additional surgery.
• C. Sarcoma with distant metastases.

Three prongs. Any one meets the listing. No residual functional capacity analysis needed if the medical evidence lines up. That's why bone sarcoma cases move faster than most disability claims when the documentation is clean.

Which cancers Listing 13.11 covers

Osteosarcoma

The most common primary bone cancer in the US. About 1,000 new cases per year, with two age peaks: teens and young adults, and older adults over 65 (often secondary to Paget's disease or prior radiation). Standard treatment is the MAP protocol: high-dose methotrexate plus doxorubicin plus cisplatin. Neoadjuvant chemo first, then surgery, then adjuvant chemo. Five-year survival is about 68% for localized disease, drops to 27% for metastatic disease at diagnosis, per SEER 2026 data.

Chondrosarcoma

Cartilage-based tumor. About 1,000 cases per year, mostly in adults over 40. The big problem: conventional chondrosarcoma is chemo-resistant and radiation-resistant. Surgery is the only real cure, so unresectable tumors carry brutal prognosis. Dedifferentiated chondrosarcoma has 5-year survival below 15%. Grade 1 tumors, on the other hand, sit near 90% at 5 years with clean resection.

Ewing sarcoma

Small round blue cell tumor of bone (and sometimes soft tissue). About 200 US cases per year in kids and young adults, plus another 200 in adolescents and young adults. Standard treatment uses VDC/IE alternating cycles: vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide, plus local control (surgery, radiation, or both). Localized disease: 5-year survival around 70%. Metastatic disease at diagnosis: 30% or lower.

Chordoma

Rare, slow-growing tumor of notochord remnants. About 300 US cases per year. Skull base, mobile spine, and sacrum are the hotspots. Chordoma is famously radioresistant to conventional radiation but responds better to proton beam or carbon ion therapy. Surgical margins are the key variable. Recurrence is common even after "clean" resection.

Prong A: Inoperable or unresectable

This is the fastest path when your surgeon has already documented that the tumor can't come out. "Inoperable" and "unresectable" aren't identical concepts, and SSA reads them both:

• Inoperable means surgery can't be performed safely. Reasons include tumor location wrapped around critical structures (great vessels, spinal cord, brainstem), patient comorbidities that make anesthesia lethal, or extent of disease that would require amputation the patient refuses or that would still leave positive margins.
• Unresectable means complete removal with negative margins isn't possible. You could technically cut, but you'd leave microscopic disease behind. For bone sarcoma, positive-margin resection is treated as failure by most tumor boards.

You want the surgical oncologist's note in your file explicitly stating one of these terms. Not "we chose not to operate because chemo works better." That's a treatment strategy note, and DDS examiners will bounce it. You want language like "The tumor is unresectable due to encasement of the sciatic nerve and posterior tibial artery" or "This tumor is inoperable given the patient's cardiac ejection fraction of 22% and prior thoracic radiation."

What proof SSA wants

1. Pathology confirming primary bone or joint sarcoma (with tumor type: osteo, chondro, Ewing, chordoma, or other).
2. Imaging showing tumor extent (MRI plus CT is standard; PET-CT for staging).
3. A tumor board note or surgical oncology consult documenting the unresectable or inoperable determination.
4. Any biopsy or interventional radiology reports supporting the diagnosis.

Prong B: Recurrent except for local recurrence controlled by additional surgery

Prong B is where a lot of cases either fly through or get denied. The rule has a carve-out: local recurrence that gets controlled with more surgery does not qualify. Everything else does. This includes:

• Regional recurrence in nearby soft tissue or lymph nodes.
• Distant recurrence (though this also triggers Prong C).
• Local recurrence that keeps coming back after surgery.
• Local recurrence that cannot be controlled by additional surgery because the anatomy has changed or margins are no longer achievable.

The trap: if your surgeon does a wide local excision on a recurrent tumor and gets clean margins, and your follow-up imaging is clean 3 months later, that is "local recurrence controlled by additional surgery." SSA reads that carve-out literally. You'd need to meet Prong A or C instead.

Chondrosarcoma and Prong B

Chondrosarcoma is prong B's classic customer. It recurs locally in 30-50% of cases even after wide resection. Grade 1 tumors can recur as dedifferentiated tumors, which are essentially a different, deadlier cancer. Chordoma is similar. The recurrence pattern in chordoma is about 40% at 5 years post-resection. Both of these cancers eat through the "local recurrence controlled by additional surgery" carve-out because they keep coming back.

Osteosarcoma and Ewing sarcoma recurrence

These typically recur in the lungs. That's distant metastasis, which puts you in Prong C automatically. Isolated local recurrence in these cancers is less common but does happen. If it's controlled with resection and clean margins, the carve-out kicks in. If it recurs again or if the resection can't get clean margins, Prong B applies.

Prong C: Distant metastases

Simplest of the three. If imaging shows the sarcoma has spread beyond the primary site and regional lymph nodes to a distant organ (lung, liver, brain, other bones, distant soft tissue), Prong C is met. No need to prove treatment failure. No need to wait for progression. The metastasis itself is enough.

The most common metastatic sites for bone sarcoma:

• Osteosarcoma: lungs (85% of metastatic cases), then other bones (skip lesions), then rarely liver or lymph nodes.
• Ewing sarcoma: lungs, then bone marrow, then other bones.
• Chondrosarcoma: lungs, then other bones, then rarely liver.
• Chordoma: lungs, then bone, then lymph nodes, then rare brain metastases from skull base tumors.

Documentation for Prong C is straightforward: CT chest showing pulmonary nodules confirmed as metastatic sarcoma (biopsy preferred but not always required if imaging is characteristic and clinical context fits), or PET-CT with FDG-avid distant lesions, or bone scan showing distant osseous metastases.

What SSA reads carefully in the medical file

DDS medical consultants are looking at more than just the listing prong. They want to see:

1. Confirmed pathology. Bone sarcoma diagnoses come from either open biopsy or CT-guided core biopsy. The path report should name the tumor type, grade, and any relevant molecular findings (EWSR1 rearrangement for Ewing, IDH1/2 mutation for chondrosarcoma, brachyury positivity for chordoma).
2. Complete staging workup. Local MRI, chest CT, bone scan or PET-CT. AJCC 8th edition staging with T, N, M, and grade.
3. Treatment history and response. Chemo protocol used, cycles completed, imaging response, surgical outcome, radiation dose and technique.
4. Functional status. ECOG or Karnofsky score, ability to ambulate, need for assistive devices, pain level, opioid regimen.

The role of modern treatments in your case

MAP chemotherapy for osteosarcoma

Methotrexate + Adriamycin (doxorubicin) + Platinum (cisplatin). Standard neoadjuvant and adjuvant protocol. Cycles run 10-12 weeks pre-op, then 20 weeks post-op depending on tumor necrosis response. Patients often can't work through this treatment period. Even after treatment completion, cardiac and renal toxicity from cisplatin and doxorubicin can leave lasting functional limitations that SSA weighs into any RFC assessment if the listing prongs aren't met.

Mifamurtide

Approved in Europe for osteosarcoma. Not FDA-approved in the US as of 2026, but sometimes accessed through compassionate use. Not commonly referenced in SSA files but relevant if your treatment plan includes it.

Denosumab

Used for giant cell tumor of bone (which lives under a different listing, but sometimes discussed alongside sarcoma). Also used to reduce skeletal-related events in metastatic bone disease. If you're on denosumab for metastatic sarcoma, it signals distant disease, which supports Prong C.

Limb salvage vs amputation

The current standard for extremity osteosarcoma and Ewing is limb salvage with endoprosthetic reconstruction, when tumor location allows. Amputation is reserved for cases where limb salvage would leave positive margins or nonfunctional limbs. Either surgical route can create long-term functional deficits, but SSA doesn't require amputation to approve. What SSA cares about is whether the primary tumor met a listing prong at some point in the disease course.

Immunotherapy and targeted therapy in sarcoma

Sarcoma has been slow to benefit from checkpoint inhibitors, but a few settings apply in 2026:

• Pembrolizumab for MSI-high or high tumor mutational burden tumors, occasionally seen in chordoma and rare sarcoma subtypes.
• Regorafenib and pazopanib as later-line options in some sarcoma subtypes.
• Larotrectinib and entrectinib for NTRK-fusion tumors, rare in sarcoma but occasionally seen.

Timeline from filing to payment

Bone sarcoma cases with distant metastases (Prong C) or unresectable primary disease (Prong A) frequently qualify for Compassionate Allowance handling. That flags the case for expedited review at DDS. Realistic timelines:

State-specific considerations

Sarcoma treatment is centered at major cancer centers. If you're being treated far from home, your DDS jurisdiction is determined by your residence, not your treatment location. That matters because DDS processing speed varies. Applicants in California average 105 days at initial review. Texas averages 92 days. Florida averages 118 days. New York averages 96 days. Compassionate Allowance flags cut those times substantially, often to under 30 days.

Related reading on the sarcoma and cancer disability path: Why was my disability denied in 2026, and the general SSDI application guide.

The RFC path when the listing is a stretch

Not every bone sarcoma case meets a listing prong. Localized, resectable, non-recurrent disease with no metastases still puts you in tough shape during and after treatment, but it may not clear Listing 13.11. In that case SSA moves to the Medical-Vocational analysis, and the residual functional capacity (RFC) determination becomes central.

What builds a strong RFC in sarcoma cases when the listing doesn't hit:

• Documented lymphedema post-resection (measurable circumference differences).
• Chronic pain requiring long-acting opioid therapy.
• Chemotherapy-induced peripheral neuropathy limiting hand or foot function.
• Cardiotoxicity from doxorubicin (echocardiogram with reduced EF).
• Renal impairment from cisplatin or high-dose methotrexate.
• Prosthetic complications, gait limitations, need for assistive devices.

An RFC that limits you to sedentary work plus additional non-exertional limits (concentration, absences due to medical appointments, fatigue) can still result in a favorable decision at the ALJ hearing level under grid rules, especially if you're over 50.

Common denial reasons and how to fix them

1. Diagnosis not confirmed by biopsy

Fix: get the biopsy done, or get the tumor board note explaining why biopsy isn't feasible. Imaging alone rarely satisfies DDS.

2. Pulmonary nodules labeled "suspicious" but not "metastatic"

Fix: get one biopsied if safely accessible, or get the oncologist to write a clear letter stating these are metastatic based on the clinical context.

3. Recurrent tumor "controlled" by additional surgery

Fix: if this is your situation, Prong B doesn't apply. Look to Prong A (was the recurrent tumor unresectable before that additional surgery?) or Prong C (are there distant mets?), or go the RFC route.

4. Treatment ongoing and status uncertain

Fix: SSA can still approve based on the diagnosis and staging at time of application. Don't wait to file. Get the application in while treatment is happening.

5. Grade 1 chondrosarcoma with clean resection and no recurrence

Honest fix: this case is genuinely hard under Listing 13.11 because Grade 1 chondrosarcoma has strong prognosis after clean resection. You'll likely need to argue the RFC path plus any documented complications.

Frequently Asked Questions